Chemical volatilization device

Abstract

To provide a chemical volatilization device that can sufficiently impregnate air blown thereinto, with a chemical, and thereby can effectively volatilize the chemical.SOLUTION: A chemical volatilization device 1A comprises a chemical volatilizer 3 holding a volatilizable chemical so as to be capable of volatilizing it, and a housing container 5 housing the chemical volatilizer 3 so as to be capable of being ventilated. The housing container 5 comprises a front part 21 comprising a first opening part 10, and a back part 31 comprising a second opening part 20. The front part 21 and the back part 31 are oppositely arranged. When the front part 21 and the back part 31 are made to overlap each other, there are a region in which the first opening part 10 and the second opening part 20 overlap each other, and a region in which the first opening part 10 and the second opening part 20 do not overlap each other. The area of the region in which they overlap each other is 20-80% of the area of the first opening part 10 or the area of the second opening area 20.SELECTED DRAWING: Figure 1

Description

[Technical Field]

[0001] The present invention relates to a drug volatilization device that includes a drug volatilization body that holds a volatile drug in a volatilizable manner, and a storage container that stores the drug volatilization body in a breathable manner. [Background technology]

[0002] In a house, windows near the entrance or the balcony can be entry points for pests. One method for preventing the entry of pests is to place insect repellents at the entrance or on the balcony. As such an insect repellent, for example, a chemical volatilizer is known, which contains an insect repellent chemical and volatilizes it in the air blown into a container by the wind (see Patent Documents 1 and 2).

[0003] The chemical volatilizer described in Patent Document 1 comprises a carrier holding a volatile chemical inside a chemical container shaped like an elongated rectangular parallelepiped with an opening, and is configured to be used by hanging it from a doorknob, for example, and by blowing air into the chemical container and allowing the chemical to be absorbed into the air, the air containing the chemical is released through the opening in the chemical container and volatilized, thereby exterminating or repelling flying pests such as mosquitoes and black flies that attempt to enter through the front door.

[0004] The chemical volatilizer according to Patent Document 2 comprises a rectangular plate-shaped chemical container with an opening, which contains a carrier holding a volatile chemical, and is used by hanging it from a clothesline or handrail on a balcony, for example. The chemical is then absorbed into the chemical container, and the air containing the chemical is released through the opening in the chemical container to volatilize it, thereby exterminating or repelling flying pests such as mosquitoes and black flies that attempt to enter through windows near the balcony. [Prior art documents] [Patent documents]

[0005] [Patent Document 1] Japanese Patent Application Laid-Open No. 2013-132216 [Patent Document 2] Japanese Patent Application Laid-Open No. 2008-194034 Summary of the Invention [Problem to be solved by the invention]

[0006] In the drug volatilizer disclosed in Patent Document 1, openings are provided on the front and back portions of the drug container. Each opening on the front and back portions of the drug container is formed by a collection of numerous square holes of the same size, regularly arranged at a predetermined pitch vertically and horizontally. In the drug volatilizer of Patent Document 1, which has such openings, when the front and back portions of the drug container are overlapped, the openings on the front and back portions overlap so that they approximately coincide. Therefore, when the drug volatilizer is installed in a location other than a doorknob, air blown into the drug container from the opening on the front portion due to wind flow can easily escape to the outside of the drug container through the opening on the back portion. As a result, the air blown into the drug container may be released to the outside of the drug container without being sufficiently saturated with the drug. Therefore, there is room for improvement in terms of effectively volatilizing the drug.

[0007] In the drug volatilizer of Patent Document 2, openings are also provided on the front and back portions of the drug container. Each opening on the front and back portions of the drug container is formed by a collection of multiple window-shaped holes, and most of the holes are drilled so that they are approximately the same size and arranged when viewed projected from the front side to the back side. In the drug volatilizer of Patent Document 2 with such openings, as with the drug container of Patent Document 1, when the front and back portions of the drug container are overlapped, the openings on the front side and the openings on the back side overlap so that they approximately coincide. Therefore, as with the drug container of Patent Document 1, there is room for improvement in terms of effective drug volatilization.

[0008] The present invention has been made in consideration of the above-mentioned problems, and aims to provide a drug volatilization device that can sufficiently contain drug in the blown air, thereby effectively volatilizing the drug. [Means for solving the problem]

[0009] The characteristic configuration of the chemical volatilization device according to the present invention to solve the above problem is as follows: A drug volatilization body that holds a volatile drug in a volatilizable manner; A container that accommodates the drug volatilizer in a breathable manner; A drug volatilization device comprising: The storage container is a first surface portion having a first opening; a second surface portion having a second opening; Equipped with The first surface portion and the second surface portion are disposed opposite to each other, when the first surface portion and the second surface portion are overlapped with each other, there is a region where the first opening and the second opening overlap with each other and a region where the first opening and the second opening do not overlap with each other, The area of ​​the overlapping region is configured to be 20 to 80% of the area of ​​the first opening or the area of ​​the second opening.

[0010] According to the chemical volatilization device of this configuration, when the first surface portion and the second surface portion are overlapped, there is a region where the first opening and the second opening overlap and a region where the first opening and the second opening do not overlap, and the area of ​​the overlapping region is configured to be 20 to 80% of the area of ​​the first opening or the second opening. This configuration makes it difficult for air blown into the container from the first opening or the second opening by wind flow to escape directly to the outside of the container through the second opening or the first opening, creating a turbulent air flow inside the container, stirring up the volatile chemical from the chemical volatilizer and the air. As a result, the chemical can be sufficiently contained in the air blown into the container, and the air containing the sufficient chemical can be released to the outside of the container. Therefore, the chemical can be effectively volatilized.

[0011] In the chemical volatilization device according to the present invention, The surface area of ​​the side of the drug volatilizer facing the first surface or the second surface is 1000 to 15000 mm 2 It is preferable to set it to .

[0012] According to the chemical volatilization device of this configuration, the surface area of ​​the side of the chemical volatilization body facing the first surface portion or the second surface portion is 1000 to 15000 mm 2 Since the surface area is set to 100%, it is possible to ensure a surface area that allows the chemical agent to be effectively vaporized.

[0013] In the chemical volatilization device according to the present invention, If the surface of the first or second surface facing the drug volatilizer is considered to be a plane that can come into contact with the drug volatilizer and does not have the first opening or the second opening, it is preferable that the overlapping area when the surface of the drug volatilizer facing the plane is projected onto the plane is set to 15% or less of the total surface area of ​​the drug volatilizer.

[0014] According to the drug volatilization device of this configuration, when there is no first opening or second opening, the contact area of ​​the drug volatilizer with the surface facing the first or second surface is set to 15% or less of the entire surface area of ​​the drug volatilizer. In reality, because openings are provided on the first and second surfaces, the actual contact area can be reliably kept smaller than 15% of the entire surface area of ​​the drug volatilizer. In this way, by minimizing the portion of the drug volatilizer that can come into contact with the first or second surface, it is possible to avoid interference with drug volatilization and prevent contamination of the storage container.

[0015] In the chemical volatilization device according to the present invention, The area of ​​each of the first opening and the second opening is preferably set to 10 to 50% of the total area of ​​each of the first surface portion and the second surface portion.

[0016] According to the drug volatilization device of this configuration, the area of ​​each of the first opening and the second opening is set to 10 to 50% of the total area of ​​each of the first surface portion and the second surface portion, so that the amount of air taken in and released through the first opening and the second opening is appropriate, and excessive volatilization of the drug can be avoided while the efficacy of the drug is properly exerted, and the drug volatilization performance of the drug volatilizer can be maintained for a long period of time.

[0017] In the chemical volatilization device according to the present invention, It is preferable that each of the first opening and the second opening is formed by a group of a plurality of holes.

[0018] According to the drug volatilization device of this configuration, each of the first opening and the second opening is formed by a collection of multiple holes, so that when air is blown into the inside of the storage container from the first opening or the second opening by the wind flow and mixed with the drug from the drug volatilizer, as it passes through the multiple holes that form the second opening or the first opening, the flow of air is narrowed at each hole, thereby increasing the flow rate, thereby increasing the release rate from the storage container to the outside, and allowing the drug to be volatilized more effectively.

[0019] In the chemical volatilization device according to the present invention, The first surface portion has an intermediate portion between both end portions formed into a convex curved surface that protrudes outward from the storage container, the holes in the first surface portion are arranged from the both end portions to the intermediate portion of the first surface portion, It is preferable that the opening areas of the arranged holes are set to increase in the direction from the middle portion toward the both end portions.

[0020] According to the chemical volatilization device of this configuration, the first surface is formed as a convex curved surface with an intermediate portion between the two ends protruding outward from the storage container, and the plurality of holes in the first surface are arranged from the two ends to the intermediate portion of the first surface. As a result, when air is drawn into the storage container through the plurality of holes in the first surface, air is drawn in from an external region that diverges in a direction away from the convex curved first surface, allowing air to be drawn in from a wider external region than when the first surface is flat. Furthermore, when chemical-containing air is discharged from the inside of the storage container to the outside of the storage container through the plurality of holes in the first surface, the chemical-containing air is discharged toward an external region that diverges in a direction away from the convex curved first surface, allowing chemical-containing air to be discharged to a wider external region than when the first surface is flat. However, when the first surface is formed as a convex curved surface, the air intake volume that can be drawn into the storage container is structurally smaller at the end portions including the ends of the first surface of the storage container than at the intermediate portion including the intermediate portion of the first surface of the storage container. Therefore, in the present invention, the opening areas of the plurality of holes arranged from both ends to the middle of the first surface are set to increase in the direction from the middle to both ends, so that at the ends of the container where the air intake capacity is relatively small, air is taken in through holes with relatively large opening areas, and as a result, air can be taken in uniformly throughout the container, and the taken-in air can be uniformly saturated with the medicine.

[0021] In the chemical volatilization device according to the present invention, the holes are arranged on an imaginary spiral line drawn imaginarily on the first surface portion, the imaginary spiral line moving away from a center portion in a direction of rotation, and extending from both end portions of the first surface portion to an intermediate portion between the both end portions, It is preferable that the opening areas of the arranged holes are set to increase in the direction of rotation.

[0022] According to the drug volatilization device of this configuration, the opening area of ​​the plurality of holes arranged on the first surface portion is set to increase as the flow proceeds in the direction of the imaginary spiral. Therefore, when the air blown into the container through the second opening on the second surface portion by the wind flow is mixed with the drug from the drug volatilizer and then passes through the plurality of holes arranged on the first surface portion, the throttling effect of increasing the flow rate by throttling the air flow through each hole increases as the air approaches the center of the first surface portion and decreases as the air moves from the center toward the direction of the imaginary spiral. Therefore, the drug-containing air is released from the center of the first surface portion at a relatively high flow rate, and the flow rate of the released drug-containing air decreases as the air moves away from the center of the first surface portion toward the direction of the imaginary spiral. As a result, the drug can be released from the first surface portion on a directional spiral airflow, allowing the drug to volatilize over a longer distance.

[0023] In the chemical volatilization device according to the present invention, The ratio between the minimum opening area and the maximum opening area of ​​the holes is preferably set to 3:5 to 3:80.

[0024] According to the drug volatilization device of this configuration, the ratio between the minimum opening area and the maximum opening area of ​​the multiple hole sections is set to 3:5 to 3:80, so that the throttling effect of increasing the flow rate by restricting the air flow at each hole section results in an appropriate ratio between the amount of drug that is volatilized over a long distance at a relatively high flow rate and the amount of drug that is volatilized over a short distance at a relatively low flow rate, allowing the drug's efficacy to work appropriately.

[0025] In the chemical volatilization device according to the present invention, The hole has a circular shape or a shape including an arc portion, It is preferable that the shortest distance between the opening edge of one of the holes and the opening edge of another hole adjacent to the one hole be set to at least 1 / 6 of the diameter of the one hole.

[0026] With this configuration of drug volatilization device, adjacent holes are positioned at a distance that allows them to function as independent holes, which makes it possible to suppress mutual interference between the air blown into the storage container through one hole and another hole, and also to suppress mutual interference between the air released to the outside of the storage container through one hole and another hole, allowing for smooth intake and release of air.

[0027] In the chemical volatilization device according to the present invention, the container further includes a third surface portion having a third opening; The third surface portion preferably extends between the first surface portion and the second surface portion in a direction intersecting the first surface portion and the second surface portion.

[0028] With this configuration of drug volatilization device, in addition to air being taken in and released through the first opening and second opening provided on the first surface and second surface, air is also taken in and released through the third opening provided on the third surface, allowing the drug to be volatilized over a wider area.

[0029] In the chemical volatilization device according to the present invention, The storage container is configured by separably fitting together one container portion including the first surface portion and another container portion including the second surface portion, The one container portion has a protrusion protruding toward the inside of the receiving container, The other container portion is formed with a pair of guide portions that can be engaged with both side edges of the protrusion, When the one container part and the other container part, which are in a separated state, are brought into a fitted state, it is preferable that the protrusion be guided by the guide part.

[0030] With this configuration of drug volatilization device, when the one-side container part and the other-side container part, which are in a separated state, are fitted together, the protrusion provided on the one-side container part is guided by a pair of guide parts provided on the other-side container part, so that the relative positions of the one-side container part and the other-side container part become appropriate, and the operation of fitting the one-side container part and the other-side container part together to make the storage container usable can be performed smoothly.

[0031] In the chemical volatilization device according to the present invention, The volatile chemical has a vapor pressure of 2×10 at 30°C. -4 ~1×10 -2 It is preferable that the pyrethroid compound has a viscosity of 1000 kJ / cm2 or less.

[0032] According to the chemical vaporization device of this configuration, by holding a pyrethroid compound of a predetermined vapor pressure in a chemical vaporizer in a volatilizable manner, it is possible to achieve an effective chemical vaporization effect in applications such as exterminating or repelling pests. [Brief explanation of the drawings]

[0033] [Figure 1] FIG. 1 is a diagram showing a chemical volatilization device according to a first embodiment. [Figure 2] FIG. 2 is an explanatory diagram of the first opening. [Figure 3] FIG. 3 is an explanatory diagram of the second opening. [Figure 4] FIG. 4 is a diagram showing an overlapping area between the first opening and the second opening when the front part is placed on the back part. [Figure 5] FIG. 5 is a diagram showing an overlapping area between the first opening and the second opening when the rear part is placed on the front part. [Figure 6] FIG. 6 is a vertical cross-sectional view of the medicine volatilization device of the first embodiment. [Figure 7] FIG. 7 is a diagram showing a structure for aligning the front container portion and the rear container portion in the storage container. [Figure 8] FIG. 8 is a diagram showing a chemical volatilization device according to a second embodiment of the present invention. [Figure 9] FIG. 9 is an explanatory diagram of the first opening. [Figure 10] FIG. 10 is an explanatory diagram of the second opening. [Figure 11] FIG. 11 is a diagram showing an overlapping area between the first opening and the second opening when the front part is placed on the back part. [Figure 12] FIG. 12 is a diagram showing an overlapping region between the first opening and the second opening when the rear section is placed on the front section. [Figure 13] FIG. 13 is a vertical cross-sectional view of the medicine volatilization device of the second embodiment. DETAILED DESCRIPTION OF THE INVENTION

[0034] The present invention will be described below with reference to the drawings. However, the present invention is not intended to be limited to the embodiments described below or the configurations shown in the drawings.

[0035] First Embodiment Fig. 1 is a diagram showing a drug volatilization device 1A according to a first embodiment of the present invention. Fig. 1(a) is a perspective view of the entire drug volatilization device 1A as seen from the front. Fig. 1(b) is a perspective view of the entire drug volatilization device 1A as seen from the rear. Fig. 1(c) is a perspective view of the entire drug volatilization body 3 incorporated in the drug volatilization device 1A as seen from the front.

[0036] <Overall structure> The drug volatilization device 1A shown in Figures 1(a) and (b) comprises a drug volatilizer 3 as shown in Figure 1(c) which holds a volatile drug in a volatilizable manner, a resin storage container 5 which stores the drug volatilizer 3 in a breathable manner, and a resin hook portion 7 attached to the storage container 5.

[0037] <Drug volatilization body> The drug volatilizer used in the present invention may be a sheet-like planar structure or a three-dimensional structure made of various materials. Examples of sheet-like planar structures include naturally occurring materials such as pulp and linter, cellulosic fibers such as rayon and viscose, synthetic fibers such as polyester, polyethylene, polypropylene, and polyamide, and glass fibers. These materials may be entangled to form breathable sheets such as paper, cloth, nonwoven fabric, and felt, or resin meshes formed from resin compositions into a grid or net shape. Examples of three-dimensional structures include the drug volatilizer 3 shown in FIG. 1(c). This drug volatilizer 3 is constructed by joining multiple corrugated rods formed into rectangular waves at their peaks. The drug volatilizer 3 is formed using a resin composition containing a volatile drug, and the incorporated volatile drug is allowed to bleed onto the surface of the three-dimensional structure and volatilize from the surface.

[0038] The resin mesh of the planar structure or the resin composition that constitutes the three-dimensional structure is, for example, a composition in which a volatile agent containing an insect repellent component is contained in a resin, and is a composition that is capable of volatilizing the volatile agent contained therein, and is usually produced using resin pellets containing the volatile agent.

[0039] Specifically, the insect repellent component-containing resin pellets are prepared by kneading a volatile insect repellent component, if necessary, onto a fine powder carrier, and then kneading the resulting pellets with a resin. Furthermore, when the insect repellent component is transfluthrin, a crystal precipitation-preventing component is also included. These pellets can be used as masterbatches, and when additional resins are mixed and kneaded with these pellets as needed, they become resin compositions that can be used as materials for producing various resin molded products. The insect repellent component-containing resin pellets of this invention can be transported and stored in this form, preventing bleeding, crystal precipitation, and other problems during transport and storage.

[0040] The resin is not particularly limited as long as it can gradually volatilize the volatile chemicals contained therein from the surface, either directly or when used with a carrier as described below. Examples include polyolefin resins such as polyethylene (PE) (e.g., branched low-density polyethylene (LDPE) and linear low-density polyethylene (LLDPE)) and polypropylene (PP), as well as polyolefin copolymers of these with carboxylic acid esters (e.g., vinyl acetate, methyl methacrylate, ethyl methacrylate). Such carboxylic acid esters are effective in controlling the volatilization of volatile chemicals from the resin surface, and generally, the higher the carboxylic acid ester to polyolefin resin ratio, the more likely it is that the bleeding rate of the volatile chemicals will be slowed. In the present invention, ethylene-vinyl acetate copolymers (EVA) and ethylene-methyl methacrylate copolymers (EMMA), which contain 1 to 35 wt. % carboxylic acid esters relative to the polyolefin resin, are preferably used. Furthermore, polymer blends containing polyolefin copolymers and olefin homopolymers at adjusted ratios can also be used, and other polymeric compounds, such as styrene-based elastomers, can also be added as needed. The carboxylic acid ester means an unsaturated carboxylic acid ester or a vinyl carboxylic acid ester.

[0041] In particular, in this invention, it is particularly preferable to contain an ethylene-vinyl acetate copolymer (ethylene-vinyl acetate resin). The ethylene-vinyl acetate copolymer not only functions as a resin component constituting the pellets, but also acts as a bleeding regulator for the insect repellent components transfluthrin, metofluthrin, and profluthrin. When the insect repellent component is transfluthrin or profluthrin, the blending amount of this ethylene-vinyl acetate copolymer is 5% by mass or more, preferably 10% by mass or more, and more preferably 15% by mass or more, based on the total pellet mass. On the other hand, the upper limit is preferably 50% by mass or less, more preferably 45% by mass or less. Note that when the insect repellent component is metofluthrin, a blending amount of 5% by mass or more and 35% by mass or less is appropriate. Furthermore, when the insect repellent component is a mixture mainly containing metofluthrin, a blending amount of 10% by mass or more and 35% by mass or less is appropriate.

[0042] The volatile agent containing the above-mentioned insect repellent component is not particularly limited as long as the active ingredient is volatile, and can be used in combination with other ingredients such as repellents, fragrances, deodorizers, antifungal agents, and antibacterial agents.

[0043] Examples of the insect repellent component include pyrethroid insecticides such as transfluthrin, metofluthrin, empenthrin, profluthrin, allethrin, furamethrin, prallethrin, resmethrin, phthalthrin, fenothrin, and natural pyrethrins; organophosphate insecticides such as dichlorvos, fenitrothion, and malathrin; and insect growth regulators such as methoprene and hydroprene. Among these, those with a vapor pressure of 2×10 at 30°C are preferred. -4 ~1×10 -2 Preferably, the compound is selected from the group consisting of pyrethroid compounds with a viscosity of mmHg, such as transfluthrin, metofluthrin, empenthrin, and profluthrin. These compounds may contain optical isomers or geometric isomers based on asymmetric carbons or unsaturated bonds, and it goes without saying that the present invention also encompasses each of these isomers alone or any mixture thereof.

[0044] Examples of the repellents include 1-methylpropyl 2-(2-hydroxyethyl)-1-piperidinecarboxylate (icaridin), ethyl butylacetylaminopropionate (IR3535), N,N-diethyltoluamide (DEET), dimethyl phthalate, dibutyl phthalate, 2-ethyl-hexanediol, dibutyl succinate, and p-menthane-3,8-diol.

[0045] Examples of the fragrances include citronella oil, orange oil, lemon oil, lime oil, yuzu oil, lavender oil, peppermint oil, eucalyptus oil, jasmine oil, cypress oil, green tea essential oil, limonene, α-pinene, linalool, geraniol, phenylethyl alcohol, amyl cinnamic aldehyde, and benzyl acetate.

[0046] Examples of the deodorant include volatile ones such as hiba oil, hinoki oil, bamboo extract, mugwort extract, tung oil, and pyruvic acid esters such as ethyl pyruvate and phenylethyl pyruvate.

[0047] Examples of the antifungal agent include 2-n-octyl-4-isothiazolin-3-one, isopropylmethylphenol, and orthophenylphenol.

[0048] Examples of the antibacterial agent include hinokitiol, tetrahydrolinalool, eugenol, citronellal, and allyl isothiocyanate.

[0049] The volatile chemical-containing resin pellets may optionally contain a fine powder carrier such as talc, alumina, silica, microcrystalline silica (known as white carbon), finely powdered silicic acid, diatomaceous earth, zeolites, clay minerals, or wood flour, and may further contain colorants, stabilizers, antistatic agents, etc. The use of a fine powder carrier allows the volatile chemicals, such as the insect repellent components, to be supported within the pellets. Furthermore, a convenient resin composition production process can be employed in which a masterbatch containing a high concentration of the volatile chemical is prepared in a first step, and then further diluted with a resin to a predetermined concentration in a second step. Furthermore, interconnected bubbles may form from the interior of the resin composition to the surface, making it easier for the volatile chemicals inside to bleed to the surface.

[0050] The content of the volatile chemical in the resin composition is determined appropriately depending on the type of volatile chemical used, the type of resin, the usage environment, the usage period, etc. The longer the usage period, the higher the content of the volatile chemical needs to be, and it is appropriate to set it in the range of 1 to 20 mass%.

[0051] The molding method is not particularly limited, and extrusion molding, injection molding, press molding, vacuum molding, etc. can be used, with extrusion molding and injection molding being particularly preferred.

[0052] When the volatile chemical substance of this invention is stored in the storage container 5 described below and used, it exhibits excellent insect repellent effects based on insecticidal or repellent effects against many insects and other arthropods, specifically mosquitoes such as Culex pipiens molestus and Aedes albopictus, black flies, midges, midges, flies, moths, wasps, and spiders.

[0053] <Containment Container> 1(a) and 1(b), the storage container 5 has a generally rectangular parallelepiped shape that is elongated in the vertical direction when in use, and comprises a front container portion 11 that constitutes the front side, and a rear container portion 13 that constitutes the rear side. The front container portion 11 and the rear container portion 13 are kept fitted together by mutually engageable locking means 15 provided at required locations, and can be separated from each other by releasing the locking state of the locking means 15, allowing the drug volatilizer 3 to be inserted into and removed from the storage container 5. In the following description, unless otherwise specified, "drug" refers to the volatile drug described above.

[0054] As shown in FIG. 1(a), the front container portion 11 includes a front portion 21, an upper portion 23, a lower portion 25, and left and right side portions 27. These side portions 21, 23, 25, and 27 are all made of plate-like members. The front portion 21 is formed as a convex curved surface with both vertical ends and an intermediate portion between the two ends projecting outward from the storage container 5 (forward in this example). The upper and lower edges of the front portion 21 are integrally connected to the upper and lower edges, respectively, in a direction intersecting the front portion 21 (horizontal in this example) and extending rearward. The side portions 27 are integrally connected to the left and right edges of the front portion 21 in a direction intersecting the front portion 21 (horizontal in this example) and extending rearward.

[0055] As shown in FIG. 1(b), the rear container portion 13 includes a rear portion 31, an upper portion 33, a lower portion 35, and left and right side portions 37. These side portions 31, 33, 35, and 37 are all made of plate-like members. The rear container portion 31 is formed in a band shape extending flat in the vertical direction. The upper and lower edges of the rear container portion 31 are integrally connected to the upper and lower edges of the rear container portion 31, respectively, so as to extend forward in a direction intersecting the rear container portion 31 (horizontally in this example). The left and right edges of the rear container portion 31 are integrally connected to the side portions 37, so as to extend forward in a direction intersecting the rear container portion 31 (horizontally in this example). The rear container portion 13 is provided with a required protrusion 41 to ensure a gap between the rear container portion 13 and the door surface when the chemical volatilization device 1A is hung on a doorknob. It also has an adjustment hole / opening 43 for engaging the hook portion 7.

[0056] Here, the front portion 21 corresponds to the "first surface portion" of the present invention. The back portion 31 corresponds to the "second surface portion" of the present invention. The side surface portion 61 of the storage container 5, including the upper surface portions 23, 33, the lower surface portions 25, 35, and the side surface portions 27, 37 of the front-side container portion 11 and the back-side container portion 13, corresponds to the "third surface portion" of the present invention.

[0057] <First opening> FIG. 2 is an explanatory diagram of the first opening 10. As shown in FIG. 2, the front portion 21 has the first opening 10. The first opening 10 is formed by a collection of multiple holes 45A, 45B drilled in the front portion 21 in a predetermined arrangement. In this example, the first opening 10 includes multiple circular holes 45A and multiple teardrop-shaped holes 45B including an arc portion that combines a portion of a circle and a portion of a rounded triangle. The multiple holes 45B are arranged near the center position in the up-down direction of the front portion 21. The multiple holes 45B are arranged at a predetermined pitch in the up-down and left-right directions so that the shape of an envelope that envelops all of the multiple holes 45B bulges in the up-down direction. The multiple holes 45A are arranged from both ends of the front portion 21 in the up-down direction to the intermediate portion near the multiple holes 45B. The plurality of holes 45A are arranged at a predetermined pitch in the vertical and horizontal directions so that the intervals between the plurality of holes 45B are gradually increased in the direction toward both ends of the front portion 21 in the vertical direction. Note that the first opening 10 is mostly made up of the holes 45A. Hereinafter, when the hole portions 45A and the hole portions 45B are collectively referred to as the hole portions 45, they will be referred to as the hole portions 45.

[0058] The opening areas of the plurality of holes 45A arranged as described above are set to increase in the direction from the middle to both ends in the up-down direction of the front surface portion 21.

[0059] <Area of ​​the first opening> The area of ​​the first opening 10 formed by a collection of the holes 45 is preferably set to 10 to 50% of the entire area of ​​the front surface portion 21, and more preferably set to 10 to 30%.

[0060] As described above, by setting the area of ​​the first opening 10 to within the range of 10 to 50% of the entire area of ​​the front portion 21, the amount of air taken in and released through the first opening 10 is appropriate, and excessive volatilization of the drug can be avoided while the efficacy of the drug is properly exerted, thereby maintaining the drug volatilization performance of the drug volatilizer 3 for a long period of time. If the area of ​​the first opening 10 is less than 10% of the entire area of ​​the front portion 21, there is a risk that the efficacy of the drug will not be fully exerted. If the area of ​​the first opening 10 is greater than 50% of the entire area of ​​the front portion 21, there is a risk that the drug volatilization performance of the drug volatilizer 3 will not be maintained for a long period of time due to excessive volatilization of the drug.

[0061] <Hole area ratio on the front side> Here, the entire area of ​​the front portion 21 as viewed from the front is divided into three equal parts in the vertical direction, and an upper end area 101A, a lower end area 101B, and an intermediate area 101C between these end areas 101A and 101B are defined. In this case, the ratio of the opening area of ​​any one of the plurality of holes 45 provided in the intermediate area 101C to the opening area of ​​any one of the plurality of holes 45 provided in the upper end area 101A and the lower end area 101B is preferably set to be 6:1 to 6:36.

[0062] As described above, by setting the opening area ratio of hole 45 in the range of 6:1 to 6:36, it is possible to keep the unevenness in the amount of air taken in and released through first opening 10 within a predetermined tolerance range in the vertical region of front portion 21, and to prevent the drug contained in drug volatilizer 3 from being partially and excessively reduced in the vertical direction. If the opening area ratio of hole 45 is outside the range of 6:1 to 6:36, the unevenness in the amount of air taken in and released through first opening 10 will exceed the predetermined tolerance range and become excessive, which may result in the drug contained in drug volatilizer 3 being partially and excessively reduced in the vertical direction.

[0063] <Maximum and minimum hole area ratio on the front side> In the front portion 21, the ratio between the minimum opening area and the maximum opening area of ​​the plurality of holes 45 is preferably set to 3:5 to 3:80.

[0064] As described above, by setting the maximum / minimum area ratio of the plurality of holes 45 in the range of 3:5 to 3:80, the throttling effect of increasing the flow rate by restricting the air flow through the holes 45 optimizes the ratio between the amount of drug vaporized over a long distance at a relatively high flow rate and the amount of drug vaporized over a short distance at a relatively low flow rate, thereby enabling the drug to work properly. If the maximum / minimum area ratio of the holes 45 is outside the range of 3:5 to 3:80, the balance between the amount of drug vaporized over a long distance and the amount of drug vaporized over a short distance will be poor, and the drug may not work properly.

[0065] <Shortest distance between adjacent holes> It is preferable that the shortest distance between the opening edge of one of the multiple hole portions 45 and the opening edge of another hole portion 45 adjacent to that one, that is, the distance (L1) in the example shown in Figure 2, be set to be 1 / 6 (approximately 0.2) or more of the diameter (diameter D1) of one of the hole portions 45.

[0066] As described above, by setting the shortest distance (L1) between adjacent hole portions 45 to be at least 1 / 6 of the diameter (diameter D1) of one hole portion 45, adjacent hole portions 45 are arranged at a distance that allows them to function as independent holes, which makes it possible to suppress mutual interference between the air blown into the storage container 5 through one hole portion 45 and the other hole portions 45, and also makes it possible to suppress mutual interference between the air released to the outside of the storage container 5 through one hole portion 45 and the other hole portions 45, allowing for smooth intake and release of air.

[0067] <Second opening> FIG. 3 is an explanatory diagram of the second opening 20. As shown in FIG. 3, the rear surface portion 31 has the second opening 20. The second opening 20 is formed by a collection of multiple holes 47A, 47B, and 47C drilled in the rear surface portion 31 in a predetermined arrangement. In this example, the second opening 20 includes multiple circular holes 47A that are relatively small in diameter and have the same opening area, multiple holes 47B that are larger in diameter than hole 47A and have a larger opening area, and one circular hole 47C that is larger in diameter than hole 47B and has an even larger opening area. Hole 47C is located at the center position in the vertical and horizontal directions of the rear surface portion 31, i.e., at the center position. The multiple holes 47B are located on both left and right sides of hole 47C at predetermined intervals. Some of the multiple holes 47A surround hole 47C and multiple holes 47B, and are arranged at a predetermined pitch in the vertical and horizontal directions so that the shape of the envelope enveloping all of the selected holes 47A bulges in the vertical direction. The remaining holes 47A are arranged from positions near both ends of the rear surface 31 in the vertical direction to an intermediate portion near the selected holes 47A. The remaining holes 47A are arranged at a predetermined pitch in the vertical and horizontal directions so that the spacing from the selected hole 47A to the selected hole 47A gradually increases in the direction toward both ends of the rear surface 31 in the vertical direction. Note that the second opening 20 is mostly composed of hole 47A. Hereinafter, hole 47A, hole 47B, and hole 47C will be collectively referred to as hole 47.

[0068] <Area of ​​the second opening> The area of ​​the second opening 20 formed by a group of the holes 47 is preferably set to 10 to 50% of the entire area of ​​the back surface portion 31, and more preferably set to 10 to 30%.

[0069] As described above, by setting the area of ​​the second opening 20 to within the range of 10 to 50% of the entire area of ​​the back portion 31, the amount of air taken in and released through the second opening 20 is appropriate, and excessive volatilization of the drug can be avoided while the efficacy of the drug is properly exerted, thereby maintaining the drug volatilization performance of the drug volatilizer 3 for a long period of time. If the area of ​​the second opening 20 is less than 10% of the entire area of ​​the back portion 31, there is a risk that the efficacy of the drug will not be fully exerted. If the area of ​​the second opening 20 is greater than 50% of the entire area of ​​the back portion 31, there is a risk that the drug volatilization performance of the drug volatilizer 3 will not be maintained for a long period of time due to excessive volatilization of the drug.

[0070] <Ratio of hole area on the back side> Here, the entire area of ​​the back portion 31 as viewed from the rear is divided into three equal parts in the vertical direction, and an upper end area 103A, a lower end area 103B, and an intermediate area 103C between these end areas 103A and 103B are defined. In this case, the ratio of the opening area of ​​any one of the plurality of holes 47 provided in the intermediate area 103C to the opening area of ​​any one of the plurality of holes 47 provided in the upper end area 103A and the lower end area 103B is preferably set to be 6:1 to 6:36.

[0071] As described above, by setting the opening area ratio of hole 47 in the range of 6:1 to 6:36, it is possible to keep the unevenness in the amount of air taken in and released through second opening 20 within a predetermined tolerance range in the vertical region of back surface portion 31, and to prevent the drug contained in drug volatilizer 3 from being partially excessively reduced in the vertical direction. If the opening area ratio of hole 47 is outside the range of 6:1 to 6:36, the unevenness in the amount of air taken in and released through second opening 20 will exceed the predetermined tolerance range and become excessive, which may result in the drug contained in drug volatilizer 3 being partially excessively reduced in the vertical direction.

[0072] <Maximum and minimum hole area ratio on the rear side> In the rear surface portion 31, the ratio between the minimum opening area and the maximum opening area of ​​the plurality of holes 47 is preferably set to 3:5 to 3:80.

[0073] As described above, by setting the maximum / minimum area ratio of multiple holes 47 in the range of 3:5 to 3:80, the throttling effect of increasing the flow rate by restricting the air flow through holes 47 optimizes the ratio between the amount of drug vaporized over a long distance at a relatively high flow rate and the amount of drug vaporized over a short distance at a relatively low flow rate, allowing the drug to work properly. If the maximum / minimum area ratio of holes 47 is outside the range of 3:5 to 3:80, the balance between the amount of drug vaporized over a long distance and the amount of drug vaporized over a short distance will be poor, and the drug may not work properly.

[0074] <Shortest distance between adjacent holes> The shortest distance between the opening edge of one hole 47 among the plurality of holes 47 and the opening edge of another hole 47 adjacent to the one hole 47, that is, the distance (L 11 ,L 13 ,L 21 ) is the diameter of one hole portion 47 (diameter D 10 ,D 20 ) or more (approximately 0.2).

[0075] As described above, the shortest distance (L 11 ,L 13 ,L 21 ) is the diameter (D 10 ,D 20 ), adjacent holes 47 are arranged at a distance that allows them to function as independent holes, which makes it possible to suppress mutual interference between the air blown into the storage container 5 through one hole 47 and the other hole 47, and also makes it possible to suppress mutual interference between the air released to the outside of the storage container 5 through one hole 47 and the other hole 47, thereby enabling smooth intake and release of air.

[0076] <Overlapping area ratio between the first opening and the second opening> Fig. 4 is a diagram showing the overlapping area between first opening 10 and second opening 20 when front portion 21 is placed on back portion 31. As shown in Fig. 4, when front portion 21 and back portion 31 are placed on top of each other and viewed from the front side, there is an area where hole 45 constituting first opening 10 and hole 47 constituting second opening 20 overlap (the area hatched in Fig. 4), and an area where hole 45 and hole 47 do not overlap. The area of ​​the overlapping area between hole 45 and hole 47 is preferably set to be 20 to 80% of the area of ​​hole 47 constituting first opening 10.

[0077] Fig. 5 is a diagram showing the overlapping area between first opening 10 and second opening 20 when rear section 31 is placed on front section 21. As shown in Fig. 5, when front section 21 and rear section 31 are placed on top of each other and viewed from the rear side, there is an area where hole 45 constituting first opening 10 and hole 47 constituting second opening 20 overlap (the area hatched in Fig. 5), and an area where hole 45 and hole 47 do not overlap. The area of ​​the overlapping area between hole 45 and hole 47 is preferably set to be 20 to 80% of the area of ​​hole 47 constituting second opening 20.

[0078] <Proportion of contact area with container to total surface area of ​​volatile pharmaceutical agent> 6 is a longitudinal sectional view of the medicine volatilization device 1A. In FIG. 6, the surface area of ​​the surface 3a of the medicine volatilization body 3 facing the front part 21 is 1000 to 6000 mm 2 Preferably set to 1000 to 5000 mm 2 More preferably, it is set to 1000 to 4000 mm 2 The surface area of ​​the surface 3b of the drug volatilizer 3 facing the back surface 31 is set to 1000 to 6000 mm 2 Preferably set to 1000 to 5000 mm 2 More preferably, it is set to 1000 to 4000 mm 26, when the surface 31a of the back portion 31 facing the drug volatilizer 3 is considered to be a plane that can come into contact with the drug volatilizer 3 and does not have the second opening 20, it is preferable that the overlapping area when the surface 3b of the drug volatilizer 3 facing the plane is projected onto the plane is set to 15% or less of the entire surface area of ​​the drug volatilizer 3. Note that the surface area of ​​the surface 3a (3b) of the drug volatilizer 3 facing the front portion 21 (back portion 31) is the area of ​​only the surface 3a (3b), and does not include the surface area including the depth portion of the three-dimensional structure (the column structure 3c between the surface 3a and the surface 3b). Furthermore, the surface 3b of the drug volatilizer 3 facing the plane is the surface of only the surface 3b, and does not include the surface of the column structure 3c.

[0079] As described above, when the ratio of the contactable area with the storage container 5 to the total surface area of ​​the drug volatilizer 3 is set to 15% or less, the actual contactable area can be reliably kept smaller than 15% of the total surface area of ​​the drug volatilizer 3 because the hole 47 constituting the second opening 20 is actually provided in the back portion 31. In this way, by making the portion of the drug volatilizer 3 that can come into contact with the back portion 31 as small as possible, it is possible to avoid hindering the evaporation of the drug and prevent contamination of the storage container 5. Note that, as described above, the front portion 21 is formed as a convex curved surface that protrudes forward (to the left in FIG. 6), so there is almost no portion where the drug volatilizer 3 can come into contact with the front portion 21, and it goes without saying that the actual contactable area can be reliably kept smaller than 15% of the total surface area of ​​the drug volatilizer 3.

[0080] As shown in FIG. 6 , front portion 21 is formed into a convex curved surface such that an intermediate portion between both vertical ends protrudes outward (forward) from storage container 5, and multiple holes 45 in front portion 21 are arranged from both vertical ends to the intermediate portion of front portion 21. As a result, when air is taken into storage container 5 through multiple holes 45 in front portion 21, air is taken in from an external region that widens in the direction away from convex curved front portion 21, allowing air to be taken in from a wider external region than when front portion 21 is flat. Furthermore, when air containing a drug is released from inside storage container 5 to the outside of storage container 5 through multiple holes 45 in front portion 21, the drug-containing air is released toward the external region that widens in the direction away from convex curved front portion 21, allowing drug-containing air to be released into a wider external region than when front portion 21 is flat.

[0081] When the front portion 21 is formed into a convex curved surface, the volume of air that can be taken into the storage container 5 is structurally smaller in the end portion 5b of the storage container 5, which includes the end of the front portion 21, than in the middle portion 5a of the storage container 5, which includes the middle portion of the front portion 21. Therefore, the opening areas of the multiple holes 45 arranged from both ends of the front portion 21 in the vertical direction to the middle portion are set to increase in the direction from the middle portion toward the both ends (see FIG. 2). As a result, at the end portion 5b of the storage container 5, which has a relatively small air intake volume, air is taken in through the holes 45, which have a relatively large opening area. As a result, air can be taken in uniformly throughout the entire storage container 5, and the taken-in air can be uniformly saturated with the medicine.

[0082] 1(a) and 1(b), the left and right side portions of the side surface 61 of the storage container 5, which are formed by the side surface 27 of the front container portion 11 and the side surface 37 of the rear container portion 13, have third openings 30. The third openings 30 are formed by a collection of multiple holes 49 in the shape of rounded rectangles that are elongated in the vertical direction. In this way, in addition to the intake and release of air through the holes 45 that constitute the first opening 10 and the holes 47 that constitute the second opening 20, air is also taken in and released through the holes 49 that constitute the third opening 30, allowing the medicine to volatilize over a wider area.

[0083] <Alignment structure of each container part in the storage container> FIG. 7 is a diagram showing the alignment structure between the front-side container part 11 and the rear-side container part 13 in the storage container 5. FIG. 7(a) is a diagram showing a state before the front-side container part 11 and the rear-side container part 13 are fitted together. FIG. 7(b) is a diagram showing a state after the front-side container part 11 and the rear-side container part 13 are fitted together. As shown in FIGS. 7(a) and 7(b), the front-side container part (one-side container part) 11 has a tongue-shaped protrusion 51 that protrudes toward the inside of the storage container 5. Meanwhile, the rear-side container part 13 has a pair of elongated plate-shaped guide parts 53 that protrude so as to be engageable with both side edges of the protrusion 51. Furthermore, the rear-side container part (other-side container part) 13 has a pair of positioning protrusions 55 that are arranged outside the pair of guide parts 53 so as to be adjacent to the pair of guide parts 53, while the front-side container part 11 has a pair of notched positioning recesses 57 that are engageable with the pair of positioning protrusions 55.

[0084] 7(a) to bring the front-side container part 11 and the rear-side container part 13, which are in a separated state as shown in Fig. 7(a), into a fitted state as shown in Fig. 7(b), the protrusions 51 are guided by the pair of guide parts 53, so that the relative positions of the front-side container part 11 and the rear-side container part 13 are appropriate, i.e., the front-side container part 11 and the rear-side container part 13 are aligned so that their centers are aligned, and finally, the engagement between the pair of positioning protrusions 55 and the pair of positioning recesses 57 reliably positions the front-side container part 11 and the rear-side container part 13 in a relative positional relationship appropriate for the fitted state. In this way, the operation of fitting the front-side container part 11 and the rear-side container part 13 together to make the storage container 5 usable can be performed smoothly.

[0085] As shown in Figures 1(a) and (b), the hook portion 7 is a string-like molded product, and both ends are provided with locking portions (not shown) for locking into the adjustment hole / opening 43 formed in the storage container 5 (rear side container portion 13).

[0086] The pesticide volatilization device 1A configured as described above, as shown in Figures 1(a) and (b), is used by hanging the pesticide volatilizer 3 inside the storage container 5, for example, by hanging it from the doorknob of a front door using the hook portion 7.The pesticide is contained in air blown into the storage container 5 through, for example, the first opening 10, and the air containing the pesticide is released and volatilized through the second opening 20 and the third opening 30, thereby exterminating or repelling flying pests such as mosquitoes, midges, and moth flies that attempt to enter through the front door.

[0087] In the chemical volatilization device 1A of the first embodiment, as shown in FIGS. 4 and 5, when the front portion 21 and the back portion 31 are overlapped, there are regions where the hole portions 45 and 47 overlap and regions where the hole portions 45 and 47 do not overlap. The area of ​​the overlapping region (the region shown by hatching in FIGS. 4 and 5) is configured to be 20 to 80% of the area of ​​the first opening 10 or the area of ​​the second opening 20. With this configuration, air blown into the storage container 5 from the first opening 10 by the wind flow is less likely to escape to the outside of the storage container 5 through the second opening 20, creating a turbulent air flow inside the storage container 5, stirring up the chemical agent from the chemical volatilizer 3 and the air. As a result, the air blown into the storage container 5 can be sufficiently saturated with the chemical agent, and the air containing the sufficient chemical agent can be released to the outside of the storage container 5. Therefore, the chemical agent can be effectively volatilized, and flying pests can be effectively exterminated or repelled.

[0088] Second Embodiment Figure 8 is a diagram showing a drug volatilization device 1B according to a second embodiment of the present invention. Figure 8(a) is a perspective view of the entire drug volatilization device 1B seen from the front. Figure 8(b) is a perspective view of the entire drug volatilization device 1B seen from the rear. Figure 8(c) is a perspective view of the entire drug volatilization body 63 incorporated in the drug volatilization device 1B seen from the front. Figures 8(d) and (e) are a plan view and a bottom view of the drug volatilization device 1B.

[0089] <Overall structure> The drug volatilization device 1B shown in Figures 8(a) and (b) comprises a drug volatilization body 63 having a three-dimensional mesh structure as shown in Figure 8(c) that holds the drug in a volatilizable manner, a resin storage container 65 that stores the drug volatilization body 63 in a breathable manner, and a resin hook portion 67 attached to the storage container 65.

[0090] <Drug volatilization body> The medicine volatilizer 63 is basically the same as the medicine volatilizer 3 used in the medicine volatilizer 1A of the first embodiment except for its size, and therefore a detailed description thereof will be omitted here.

[0091] <Containment Container> 8(a) and (b), the storage container 65 is in the form of a rectangular plate of a predetermined thickness with the plate surface facing horizontally in the posture during use, and is provided with a front-side container part 71 constituting the front side portion and a rear-side container part 73 constituting the rear side portion. The front-side container part 71 and the rear-side container part 73 are maintained in a fitted state by mutually engageable locking means 75 provided at required locations, and can be separated from each other by releasing the locking state by the locking means 75, so that the drug volatilizer 63 can be put in and taken out of the storage container 65.

[0092] The front container section 71 has a front section 81, an upper section 83, a lower section 85, and left and right side sections 87. These section sections 81, 83, 85, and 87 are all made of plate-like members. The front section 81 is formed in a rectangular shape that extends flat in the up-down and left-right directions with predetermined dimensions. The upper and lower edges of the front section 81 are integrally connected to the upper and lower edges of the front section 81, respectively, in a direction intersecting the front section 81 (in this example, the horizontal direction) and extending toward the rear. The side sections 87 are integrally connected to the left and right edges of the front section 81, respectively, in a direction intersecting the front section 81 (in this example, the horizontal direction) and extending toward the rear.

[0093] The rear-side container section 73 has a rear section 91, an upper section 93, a lower section 95, and left and right side sections 97. These section sections 91, 93, 95, and 97 are all made of plate-like members. The rear section 91 is formed in a rectangular shape that extends flat in the up-down and left-right directions with predetermined dimensions. The upper and lower edges of the rear section 91 are integrally connected to the upper and lower edges of the rear section 91, respectively, in a direction intersecting the rear section 91 (in this example, the horizontal direction) and extending forward. The side sections 97 are integrally connected to the left and right edges of the rear section 91, respectively, in a direction intersecting the rear section 91 (in this example, the horizontal direction) and extending forward.

[0094] Here, the front portion 81 corresponds to the "first surface" of the present invention. The back portion 91 corresponds to the "second surface" of the present invention. The side surface portion 121 of the storage container 65, including the upper surface portions 83, 93, the lower surface portions 85, 95, and the side surface portions 87, 97 of the front-side container portion 71 and the back-side container portion 73, corresponds to the "third surface" of the present invention.

[0095] <First opening> FIG. 9 is an explanatory diagram of the first opening 70. As shown in FIG. 9, the front portion 81 has the first opening 70. The first opening 70 is formed by a collection of multiple holes 105A and 105B drilled in the front portion 81 in a predetermined arrangement. In this example, the first opening 70 includes multiple circular holes 105A and one semicircular hole 105B. The multiple holes 105A are arranged on an imaginary spiral 100 drawn imaginarily on the front portion 81, which moves away from the center in the direction of rotation, and from both ends of the front portion 81 in the vertical direction to the intermediate portion between the ends. The single hole 105B is arranged on one side (the left side in FIG. 9) in the intermediate portion between the both ends in the vertical direction of the front portion 81. Note that the first opening 70 is mostly formed by the hole 105A. Hereinafter, when the hole 105A and the hole 105B are collectively referred to, they will be referred to as the hole 105.

[0096] The opening areas of the plurality of holes 105A arranged as described above are set to increase as they move from the center of the imaginary spiral 100 in the direction of the spiral.

[0097] <Area of ​​the first opening> The area of ​​the first opening 70 formed by a collection of the holes 105 is preferably set to 10 to 50% of the entire area of ​​the front surface portion 81, and more preferably set to 10 to 30%.

[0098] As described above, by setting the area of ​​first opening 70 to within the range of 10 to 50% of the entire area of ​​front portion 81, the amount of air taken in and released through first opening 70 is appropriate, and excessive volatilization of the drug can be avoided while the efficacy of the drug is appropriately exerted, thereby maintaining the drug volatilization performance of drug volatilizer 63 for a long period of time. If the area of ​​first opening 70 is less than 10% of the entire area of ​​front portion 81, there is a risk that the efficacy of the drug will not be fully exerted. If the area of ​​first opening 70 is greater than 50% of the entire area of ​​front portion 81, there is a risk that the drug volatilization performance of drug volatilizer 63 will not be maintained for a long period of time due to excessive volatilization of the drug.

[0099] <Hole area ratio on the front side> Here, the entire area of ​​the front portion 81 as viewed from the front is divided into three equal parts in the vertical direction to define an upper end area 201A, a lower end area 201B, and an intermediate area 201C between these end areas. In this case, the ratio of the opening area of ​​any one of the plurality of holes 105 provided in the intermediate area 201C to the opening area of ​​any one of the plurality of holes 105 provided in the upper end area 201A and the lower end area 201B is preferably set to be 6:1 to 6:36.

[0100] As described above, by setting the opening area ratio of hole 105 in the range of 6:1 to 6:36, it is possible to keep the unevenness in the amount of air taken in and released through first opening 70 within a predetermined tolerance range in the vertical region of front portion 81, and to prevent the drug contained in drug volatilizer 63 from being partially and excessively reduced in the vertical direction. If the opening area ratio of hole 105 is outside the range of 6:1 to 6:36, the unevenness in the amount of air taken in and released through first opening 70 will exceed the predetermined tolerance range and become excessive, which may result in the drug contained in drug volatilizer 63 being partially and excessively reduced in the vertical direction.

[0101] <Maximum and minimum hole area ratio on the front side> In the front portion 81, the ratio between the minimum opening area and the maximum opening area of ​​the plurality of holes 105 is preferably set to 3:5 to 3:80.

[0102] As described above, by setting the maximum / minimum area ratio of holes 105 in the range of 3:5 to 3:80, the throttling effect of increasing the flow rate by restricting the air flow through holes 105 makes it possible to appropriately balance the amount of drug vaporized over a long distance at a relatively high flow rate and the amount of drug vaporized over a short distance at a relatively low flow rate, thereby enabling the drug to function properly. If the maximum / minimum area ratio of holes 105 is outside the range of 3:5 to 3:80, the balance between the amount of drug vaporized over a long distance and the amount of drug vaporized over a short distance will be poor, and there is a risk that the drug will not function properly.

[0103] <Shortest distance between adjacent holes> The shortest distance between the opening edge of one hole 105 among the plurality of holes 105 and the opening edge of another hole 105 adjacent to the one hole 105, that is, the distance (L 31 ) is the diameter of one hole portion 105 (diameter D 30 ) or more (approximately 0.2).

[0104] As described above, the shortest distance (L 31 ) is the diameter (diameter D 30 ), adjacent holes 105 are arranged at a distance that allows them to function as independent holes, which makes it possible to suppress mutual interference between the air blown into the storage container 65 through one hole 105 and the other hole 105, and also makes it possible to suppress mutual interference between the air released to the outside of the storage container 65 through one hole 105 and the other hole 105, thereby enabling smooth intake and release of air.

[0105] <Second opening> FIG. 10 is an explanatory diagram of the second opening 80. As shown in FIG. 10, the rear surface portion 91 has the second opening 80. The second opening 80 is formed by a collection of multiple holes 107A, 107B, and 107C drilled in the rear surface portion 91 in a predetermined arrangement. In this example, the second opening 80 includes multiple circular holes 107A, multiple semicircular holes 107B, and multiple holes 107C shaped like a circle with a portion cut out. The multiple holes 107A are arranged from one end (the lower end in this example) of both vertical ends of the rear surface portion 91 to the intermediate portion between the two ends. The multiple holes 107A are arranged alternately at a predetermined pitch so that the center-to-center distance in the vertical and horizontal directions increases as one moves from the vertical intermediate portion toward the lower end. Note that the second opening 80 is mostly formed by the holes 107A. In the following description, the holes 107A, 107B, and 107C will be collectively referred to as holes 107.

[0106] The opening areas of the plurality of holes 107A arranged as described above are set to increase in the direction from the middle to the lower end in the vertical direction of the rear surface portion 91.

[0107] Here, rear surface portion 91 is provided with hole 107D, which has an extremely large opening area compared to hole 107A, hole 107B, and hole 107C, and which functions as, for example, a peephole, and keyhole-shaped hole 107E associated with hole 107D, but these hole portions 107D and 107E are not included in the openings of the present invention and are therefore excluded.

[0108] <Area of ​​the second opening> The area of ​​second opening 80 formed by a collection of holes 107 is preferably set to 10 to 50% of the entire area of ​​back surface portion 91, and more preferably set to 10 to 30%.

[0109] As described above, by setting the area of ​​the second opening 80 to be in the range of 10 to 50% of the entire area of ​​the back surface portion 91, the amount of air taken in and released through the second opening 80 is appropriate, and excessive volatilization of the drug can be avoided while the efficacy of the drug is properly exerted, thereby maintaining the drug volatilization performance of the drug volatilizer 63 for a long period of time. If the area of ​​the second opening 80 is less than 10% of the entire area of ​​the back surface portion 91, there is a risk that the efficacy of the drug will not be fully exerted. If the area of ​​the second opening 80 is greater than 50% of the entire area of ​​the back surface portion 91, there is a risk that the drug volatilization performance of the drug volatilizer 63 will not be maintained for a long period of time due to excessive volatilization of the drug.

[0110] <Ratio of hole area on the back side> Here, the entire area of ​​the rear surface portion 91 as viewed from the rear is divided into three equal parts in the vertical direction to define an upper end region 203A, a lower end region 203B, and an intermediate region 203C between these end regions. In this case, the ratio of the opening area of ​​any one of the plurality of holes 107 provided in the intermediate region 203C to the opening area of ​​any one of the plurality of holes 107 provided in the upper end region 203A and the lower end region 203B (the opening area of ​​the plurality of holes 107 substantially provided in the lower end region, since the opening areas of holes 107D and 107E are excluded) is preferably set to be 6:1 to 6:36.

[0111] As described above, by setting the opening area ratio of hole 107 in the range of 6:1 to 6:36, it is possible to keep the unevenness in the amount of air taken in and released through second opening 80 within a predetermined allowable range from the vertical middle region to the lower end region of back surface portion 91, and to prevent the drug contained in drug volatilizer 63 from being partially and excessively reduced in the vertical direction. If the opening area ratio of hole 107 is outside the range of 6:1 to 6:36, the unevenness in the amount of air taken in and released through second opening 80 will exceed the predetermined allowable range and become excessive, which may result in the drug contained in drug volatilizer 63 being partially and excessively reduced in the vertical direction.

[0112] <Maximum and minimum hole area ratio on the rear side> In the rear surface portion 91, the ratio between the minimum opening area and the maximum opening area of ​​the plurality of holes 107 is preferably set to 3:5 to 3:80.

[0113] As described above, by setting the maximum / minimum area ratio of holes 107 in the range of 3:5 to 3:80, the throttling effect of increasing the flow rate by throttling the air flow through holes 107 makes it possible to appropriately balance the amount of drug vaporized over a long distance at a relatively high flow rate and the amount of drug vaporized over a short distance at a relatively low flow rate, thereby enabling the drug to function properly. If the maximum / minimum area ratio of holes 107 is outside the range of 3:5 to 3:80, the balance between the amount of drug vaporized over a long distance and the amount of drug vaporized over a short distance will be poor, and there is a risk that the drug will not function properly.

[0114] <Shortest distance between adjacent holes> The shortest distance between the opening edge of one hole 107 among the plurality of holes 107 and the opening edge of another hole 107 adjacent to the one hole 107, that is, the distance (L 41 ) is the diameter (diameter D 40 ) or more (approximately 0.2).

[0115] As described above, the shortest distance (L 41 ) is the diameter (diameter D 40 ), adjacent holes 107 are arranged at a distance that allows them to function as independent holes, which makes it possible to suppress mutual interference between the air blown into the storage container 65 through one hole 107 and the other hole 107, and also makes it possible to suppress mutual interference between the air released to the outside of the storage container 65 through one hole 107 and the other hole 107, thereby enabling smooth intake and release of air.

[0116] <Overlapping area ratio between the first opening and the second opening> 11 is a diagram showing the overlapping area between the first opening 70 and the second opening 80 when the front portion 81 is placed on the back portion 91. As shown in Fig. 11, when the front portion 81 and the back portion 91 are placed on top of each other and viewed from the front side, there is an area where the hole 105 constituting the first opening 70 and the hole 107 constituting the second opening 80 overlap (the area hatched in Fig. 11), and an area where the hole 105 and the hole 107 do not overlap. The area of ​​the overlapping area between the hole 105 and the hole 107 is preferably set to be 20 to 80% of the area of ​​the hole 105 constituting the first opening 70.

[0117] Fig. 12 is a diagram showing the overlapping area between the first opening 70 and the second opening 80 when the rear portion 91 is placed on top of the front portion 81. As shown in Fig. 12, when the front portion 81 and the rear portion 91 are placed on top of each other and viewed from the rear side, there is an area (the area hatched in Fig. 12) where the hole 105 constituting the first opening 70 and the hole 107 constituting the second opening 80 overlap, and an area where the hole 105 and the hole 107 do not overlap. The area of ​​the overlapping area between the hole 105 and the hole 107 is preferably set to be 20 to 80% of the area (opening area) of the hole 107 constituting the second opening 80.

[0118] <Proportion of contact area with container to total surface area of ​​volatile pharmaceutical agent> 13 is a longitudinal sectional view of the medicine volatilization device 1B. In FIG. 13, the surface area of ​​the surface 63a of the medicine volatilization body 63 facing the front part 81 is 2000 to 15000 mm 2 Preferably set to 2000 to 12000 mm 2 More preferably, it is set to 2000 to 10000 mm 2 The surface area of ​​the surface 63b of the drug volatilizer 63 facing the back surface 91 is set to 2000 to 15000 mm 2 Preferably set to 2000 to 12000 mm 2 More preferably, it is set to 2000 to 10000 mm 213, when the surface 81a of the front portion 81 facing the drug volatilizer 63 is considered to be a plane that can contact the drug volatilizer 63 and does not have the first opening 70, it is preferable that the overlapping area when the surface 63a of the drug volatilizer 63 facing the plane is projected onto the plane be set to 15% or less of the entire surface area of ​​the drug volatilizer 63. Note that the surface area of ​​the surface 63a (63b) of the drug volatilizer 63 facing the front portion 81 (rear portion 91) is the area of ​​only the surface 63a (63b), and does not include the surface area including the depth portion of the three-dimensional structure (the column structure 63c between the surface 63a and the surface 63b). Furthermore, the surface 63a of the drug volatilizer 63 facing the plane is the surface of only the surface 63a, and does not include the surface of the column structure 63c.

[0119] As described above, when the ratio of the contactable area with the storage container 65 to the total surface area of ​​the drug volatilizer 63 is set to 15% or less, since the hole 105 constituting the first opening 70 is actually provided in the front portion 81, the actual contactable area can be reliably kept smaller than 15% of the total surface area of ​​the drug volatilizer 63. In this way, by making the portion of the drug volatilizer 63 that can come into contact with the front portion 81 as small as possible, it is possible to avoid interference with the drug volatilization and prevent contamination of the storage container 65.

[0120] As shown in FIGS. 8(a), (b), (d), and (e), the side surface portion 121 of the storage container 65 has a third opening 30. The side surface portion 121 also has a third opening 90. The third opening 90 is formed by a collection of multiple rounded rectangular holes 109 that are elongated in the vertical or horizontal direction. The multiple holes 109 are formed by cutting out required areas of the edge portions of the upper surface portions 83, 93, the lower surface portions 85, 95, and the side surface portions 87, 97 of the front-side container portion 71 and the rear-side container portion 73. In this way, in addition to the intake and release of air through the holes 105 that constitute the first opening 70 and the holes 107 that constitute the second opening 80, air is also taken in and released through the holes 109 that constitute the third opening 90, allowing the drug to volatilize over a wider area.

[0121] As shown in Figures 8(a) and (b), the hook portion 67 is a ring-shaped molded product that is configured to be switchable between a state in which it stands upright at the top of the storage container 65 and a state in which it is folded to the back side of the storage container 65 and stored in a hook storage portion 110 formed in the back portion 91 (not shown).

[0122] 8(a) and 8(b), the chemical volatilization device 1B configured as described above is used by hanging the chemical volatilizer 63 inside the storage container 65, for example, by hanging it from a clothesline on a balcony using the hook portion 67. Then, for example, the chemical is impregnated into the air blown into the storage container 65 through the first opening 70 or the second opening 80, and the chemical-impregnated air is released and volatilized through the second opening 80 and the third opening 90, or the first opening 70 and the third opening 90, thereby exterminating or repelling flying pests such as mosquitoes, midges, and moth flies that try to enter through the balcony window.

[0123] In the second embodiment of the drug volatilization device, as shown in FIGS. 11 and 12, when the front portion 81 and the back portion 91 are overlapped, there are regions where the hole portions 105 and 107 overlap and regions where the hole portions 105 and 107 do not overlap. The area of ​​the overlapping region (the region shown by hatching in FIGS. 11 and 12) is configured to be 20 to 80% of the area of ​​the first opening 70 or the second opening 80. With this configuration, air blown into the interior of the storage container 65 from the first opening 70 or the second opening 80 by the wind flow is less likely to escape to the outside of the storage container 65 through the second opening 80 or the first opening 70. This creates a turbulent air flow within the storage container 65, mixing the drug from the drug volatilizer 63 with the air. As a result, the air blown into the interior of the storage container 65 can be sufficiently saturated with the drug, and the air containing the sufficient drug can be released to the outside of the storage container 65. Therefore, the agent can be effectively vaporized, and flying pests can be effectively exterminated or repelled.

[0124] Furthermore, in the second embodiment of the drug volatilization device 1B, the air blown into the container 65 through the second opening 80 by the wind flow is mixed with the drug from the drug volatilizer 63, and then passes through the plurality of holes 105 that form the first opening 70. The throttling effect, which increases the flow rate by throttling the air flow through the holes 105, is achieved by configuring the opening areas of the plurality of holes 105 arranged as shown in FIG. 9 to increase in size as the air advances in the direction of the vortex 100. This results in the flow rate increasing as the air approaches the center of the front portion 81 and decreasing as the air advances from the center in the direction of the vortex 100. Therefore, the drug-containing air is released from the center of the front portion 81 at a relatively high flow rate, and the flow rate of the released drug-containing air decreases as the air moves away from the center of the front portion 81 in the direction of the vortex 100. As a result, the drug can be released from the front portion 81 on a directional spiral airflow, allowing the drug to volatilize over a greater distance.

[0125] The above describes the drug volatilization device of the present invention based on several embodiments, but the present invention is not limited to the configurations described in the above embodiments, and the configuration can be changed as appropriate within the scope of the intent thereof, such as by appropriately combining the configurations described in each embodiment. [Industrial Applicability]

[0126] The chemical volatilization device of the present invention can be particularly effectively used for exterminating or repelling flying pests such as mosquitoes, midges, and moth flies. [Explanation of symbols]

[0127] 1A, 1B Chemical volatilization device 3 Drug volatilization 5. Storage container 10 First opening 11 Front container part (one side container part) 13 Rear container part (other container part) 20 Second opening 21 Front part (first side part) 30 Third opening 31 Back part (second side part) 45 Hole 47 Hole 49 Hole 51 Protrusion 53 Information Department 61 Side part (third side part) 63 Drug volatiles 65 Containment Container 70 First opening 71 Front container part (one side container part) 73 Rear container part (other container part) 80 Second opening 81 Front part (first side part) 90 Third opening 91 Back part (second side part) 100 Virtual spirals 105 Hole 107 Hole 109 Hole 121 Side part (third side part)

Claims

1. A drug volatilization body that holds a volatile drug in a volatilizable manner; A container that accommodates the drug volatilizer in a breathable manner; A drug volatilization device comprising: The storage container is a first surface portion having a first opening formed by a collection of a plurality of holes; a second surface portion having a second opening formed by a collection of a plurality of holes; Equipped with The first surface portion and the second surface portion are disposed opposite to each other, when viewed from the first surface portion side or the second surface portion side, there is a region where the first opening and the second opening overlap, and a region where the first opening and the second opening do not overlap, an area of ​​the overlapping region is configured to be 20 to 80% of an area of ​​the hole constituting the first opening or an area of ​​the hole constituting the second opening; The first surface portion has an intermediate portion between both end portions formed into a convex curved surface that protrudes outward from the storage container, the holes in the first surface portion are arranged from the both end portions to the intermediate portion of the first surface portion, and are set so that the opening area increases as the hole advances in a direction from the intermediate portion toward the both end portions, The hole has a circular shape or a shape including an arc portion, A drug volatilization device in which the shortest distance between the opening edge of one of the hole portions and the opening edge of another hole portion adjacent to the one hole portion is set to be at least 1 / 6 of the diameter of the one hole portion.

2. A drug volatilization body that holds a volatile drug in a volatilizable manner; A container that accommodates the drug volatilizer in a breathable manner; A drug volatilization device comprising: The storage container is a first surface portion having a first opening formed by a collection of a plurality of holes; a second surface portion having a second opening formed by a collection of a plurality of holes; Equipped with The first surface portion and the second surface portion are disposed opposite to each other, when viewed from the first surface portion side or the second surface portion side, there is a region where the first opening and the second opening overlap, and a region where the first opening and the second opening do not overlap, an area of ​​the overlapping region is configured to be 20 to 80% of an area of ​​the hole constituting the first opening or an area of ​​the hole constituting the second opening; The holes in the first surface portion are arranged from both ends of the first surface portion to the intermediate portion between the both ends on a virtual spiral line drawn virtually on the first surface portion, which moves away from the center as it moves in the swirling direction, and are configured so that the opening area increases as it moves in the swirling direction.

3. The surface area of ​​the side of the drug volatilizer facing the first surface or the second surface is 1000 to 15000 mm ２ The chemical volatilization device according to claim 1 or 2, wherein the chemical volatilization device is set to:

4. A drug volatilization device as described in any one of claims 1 to 3, wherein when the surface of the first surface or the second surface facing the drug volatilizer is considered to be a plane that can come into contact with the drug volatilizer and does not have the first opening or the second opening, the overlapping area when the surface of the drug volatilizer facing the plane is projected onto the plane is set to 15% or less of the total surface area of ​​the drug volatilizer.

5. A drug volatilization device described in any one of claims 1 to 4, wherein the area of ​​each of the first opening and the second opening is set to 10 to 50% of the total area of ​​each of the first surface portion and the second surface portion.

6. A drug volatilization device described in any one of claims 1 to 5, wherein the ratio of the minimum opening area to the maximum opening area of ​​the hole portion is set to 3:5 to 3:

80.

7. The hole has a circular shape or a shape including an arc portion, A drug volatilization device as described in claim 2, wherein the shortest distance between the opening edge of one of the hole portions and the opening edge of another hole portion adjacent to the one hole portion is set to be at least 1 / 6 of the diameter of the one hole portion.

8. the container further includes a third surface portion having a third opening; A drug volatilization device described in any one of claims 1 to 7, wherein the third surface portion extends between the first surface portion and the second surface portion in a direction intersecting the first surface portion and the second surface portion.

9. The storage container is configured by separably fitting together one container portion including the first surface portion and another container portion including the second surface portion, The one container portion has a protrusion protruding toward the inside of the receiving container, The other container portion is formed with a pair of guide portions that can be engaged with both side edges of the protrusion, A drug volatilization device as described in any one of claims 1 to 8, wherein when the one-side container portion and the other-side container portion, which are in a separated state, are brought into a mated state, the protrusion portion is guided by the guide portion.

10. The volatile chemical has a vapor pressure of 2×10 at 30° C. －４ ~1 x 10 －２ The chemical volatilization device according to any one of claims 1 to 9, wherein the chemical volatilization device is a pyrethroid compound having a viscosity of mmHg.

Images